STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
Mohsen Sohi, a director of STERIS plc (STE), reported multiple equity transactions in August 2025. On 08/11/2025 the filings show a sale of 4,110 ordinary shares at a weighted average price of $241.96 per share and a related entry reflecting 4,110 ordinary shares associated with a $64.05 price. After the reported transactions, the form lists 22,361 ordinary shares beneficially owned directly by the reporting person.
Separately, on 08/08/2025 the reporting person received equity awards: a nonqualified director stock option to purchase 2,226 ordinary shares at an exercise price of $242.85 (described as fully vested and exercisable immediately), plus career restricted stock units of 772 and 506 ordinary shares. The filing notes the 506 RSUs were issued in lieu of $123,000 in fees and that career RSUs generally settle in ordinary shares six months after cessation of board service. An additional option to purchase 4,110 ordinary shares at $64.05 (fully vested) is also disclosed.
Louis Shapiro, a director of STERIS plc (STE), received a grant of 975 Career Restricted Stock Units on 08/08/2025, reported on Form 4. The RSUs are fully vested immediately and represent the right to receive one ordinary share each. Settlement is deferred until six months after the director ceases Board service. The Form 4 was filed as a single reporting person filing and signed by an authorized representative on 08/12/2025. No cash price was paid for these units and they are reported as direct beneficial ownership of 975 ordinary shares upon settlement.
STERIS plc director Shah Nirav R reported insider transactions on 08/08/2025 showing a grant of 1,407 nonqualified stock options with a $242.85 exercise price and an expiration date of 08/08/2035. The filing states these options are fully vested and exercisable immediately. The report also shows 487 Career Restricted Stock Units that are fully vested and will be settled in ordinary shares six months after the cessation of the director's board service. The filing records 1,407 options and 6,503 derivative securities beneficially owned following the reported transactions.
Martin Paul Edward, a director of STERIS plc (STE), reported equity awards on 08/08/2025: he received 1,407 nonqualified stock options with an exercise price of $242.85 and an expiration date of 08/08/2035. The filing states those options are fully vested and exercisable immediately. He also acquired 487 Career Restricted Stock Units (RSUs) that are fully vested and will be settled into ordinary shares six months after he ceases Board service. After these transactions the Form 4 lists 1,407 options and 4,562 RSUs as the amounts beneficially owned following the reported transactions. The form was signed by an authorized representative on 08/12/2025.
This disclosure is a routine Section 16 filing showing director compensation in equity form, with clear vesting and settlement mechanics described for the RSUs and immediate exercisability for the options.
Christopher S. Holland, a director of STERIS plc (STE), reported the acquisition of 975 Career Restricted Stock Units on 08/08/2025. The filing states these Career RSUs are fully vested immediately and each represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. Following the reported transaction, Mr. Holland beneficially owns 4,964 RSU-linked ordinary shares. The Form 4 was executed by an authorized representative on 08/12/2025.
In this Form 4 filing STERIS director Cynthia L. Feldmann reports a sale and new equity awards. On 08/11/2025 she sold 3,495 ordinary shares at a weighted-average price of $241.56, after which she holds 705 shares directly. The filing shows 8,663 ordinary shares held indirectly in the Cynthia L. Feldmann Revocable Trust. The report also records equity grants: on 08/08/2025 a director stock option to buy 1,407 shares at a $242.85 exercise price (exercisable immediately, expiring 08/08/2035) and 487 Career Restricted Stock Units that are fully vested and will be settled in ordinary shares six months after cessation of Board service. A director stock option with a $114.74 exercise price and 3,495 underlying shares is also listed with an exercisable date shown as 08/09/2028. The form is signed by an authorized representative on 08/12/2025.
Steris director Richard C. Breeden reported awards and grants dated 08/08/2025 in a Form 4 filing. The report shows the grant of 1,704 director stock options with an exercise price of $242.85 and an expiration date of 08/08/2035; the filing states these nonqualified stock options are fully vested and exercisable immediately. The filing also discloses 842 Career Restricted Stock Units (487 and 355 units) that are fully vested and will be settled in ordinary shares six months after the director ceases board service. Some awards were issued in lieu of fees ($25,000 for options and $86,000 for RSUs). Following the reported transactions, the reporting person beneficially owned 19,545 ordinary shares.
Alegria Esther M., a director of STERIS plc (STE), reported equity awards on Form 4 dated 08/08/2025. The filing shows an acquisition of 1,407 nonqualified stock options at an exercise price of $242.85 and 487 Career Restricted Stock Units (RSUs). The filing states the options are fully vested and exercisable immediately and carry an expiration date of 08/08/2035. Each Career RSU represents the right to one ordinary share and is fully vested but will be settled in shares six months after the director ceases Board service. The Form reports total beneficial ownership following these transactions of 2,896 ordinary shares and was signed by an authorized representative on 08/12/2025.
Karen L. Burton, VP & CAO and a company officer of STERIS plc (STE), reported a sale and an outstanding option in a Form 4 filing. On 08/11/2025 she sold 7,900 ordinary shares at a weighted average price of $241.73 per share (sales ranged from $241.33 to $242.32), reducing her direct beneficial ownership to 5,994 ordinary shares.
She continues to hold a fully vested employee stock option to purchase 7,900 ordinary shares at a strike price of $114.22 that originated from the company’s March 2019 redomiciliation exchange. Of the remaining shares, 3,216 are restricted and vest in scheduled tranches between October 1, 2025 and June 5, 2028.
Form 144 notice for STERIS plc (STE) shows a proposed sale of 3,781 ordinary shares executed through Charles Schwab with an aggregate market value of $914,084 and listing the shares outstanding as 98,490,606. The table indicates the shares were acquired and disposed on 08/12/2025 through an employee stock option exercise with the payment described as a broker payment for a cashless exercise. The filing also discloses a prior sale during the past three months: 4,110 shares sold on 08/11/2025 for $993,562. The notice includes the broker name and exchange (Charles Schwab & Co.; NYSE) and the mandatory representation that the seller is not aware of undisclosed material adverse information.